Quanterix Corporation announces leadership and governance enhancements to fuel the next phase of growth.
The Company appoints Garret Hampton and Alan Sachs to the Board.
William Donnelly named Executive Chair and Jeffrey Elliott as Lead Independent Director.
New Board Members
Garret Hampton and Alan Sachs, accomplished life sciences executives, join the Board.
Executive Chair Appointment
William Donnelly transitions from non-Executive Chair to Executive Chair of the Board.
Lead Independent Director
Jeffrey Elliott takes on the role of Lead Independent Director in the Company's governance structure.
- The changes aim to support Quanterix's growth initiatives in expanding biomarker menus and launching products like LucentAD Complete™ for Alzheimer's diagnosis.
- The Company focuses on accelerating growth synergies from the Akoya acquisition for continued leadership in the diagnostics sector.
Quanterix positions itself for sustained leadership in healthcare innovation and value creation, backed by a strengthened Board and enhanced governance structure.